Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review

[1]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[2]  Philipp Dahm,et al.  Evidence‐based urology in practice: when to believe a subgroup analysis? , 2010, BJU international.

[3]  E. Akl,et al.  Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review , 2008, Journal of experimental & clinical cancer research : CR.

[4]  Gordon H Guyatt,et al.  GrADe : what is “ quality of evidence ” and why is it important to clinicians ? rATING quALITY of evIDeNCe AND STreNGTH of reCommeNDATIoNS , 2022 .

[5]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[6]  G. Moneta,et al.  Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer , 2008 .

[7]  E. Akl,et al.  Oral anticoagulation may prolong survival of a subgroup of patients with cancer: a cochrane systematic review. , 2007, Journal of experimental & clinical cancer research : CR.

[8]  Russell D Hull,et al.  Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. , 2006, The American journal of medicine.

[9]  Jawed Fareed,et al.  Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period , 2006, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[10]  S. Goldhaber,et al.  Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism , 2005, Vascular medicine.

[11]  S. Schulman,et al.  Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran , 2005, Thrombosis and Haemostasis.

[12]  S. Daskalopoulou,et al.  Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. , 2005, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[13]  M. Prins,et al.  Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Francis,et al.  Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. , 2005, JAMA.

[15]  T. Wakefield.  Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran , 2004 .

[16]  S. Schulman,et al.  Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. , 2003, The New England journal of medicine.

[17]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[18]  A. Iorio,et al.  Low‐molecular‐weight heparin for the long‐term treatment of symptomatic venous thromboembolism: meta‐analysis of the randomized comparisons with oral anticoagulants , 2003, Journal of thrombosis and haemostasis : JTH.

[19]  A. Iorio,et al.  Low-Molecular-Weight Heparin and Cancer Survival: Review of the Literature and Pooled Analysis of 1,726 Patients Treated for at Least Three Months , 2003, Pathophysiology of Haemostasis and Thrombosis.

[20]  M. Prins,et al.  Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. , 2003, The New England journal of medicine.

[21]  J. Beckman,et al.  Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism , 2003, Thrombosis and Haemostasis.

[22]  M. Gent,et al.  An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. , 2003, Thrombosis research.

[23]  Yves Gruel,et al.  Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. , 2002, Archives of internal medicine.

[24]  G. Guyatt,et al.  Clinical expertise in the era of evidence-based medicine and patient choice. , 2002, Vox sanguinis.

[25]  Gordon H Guyatt,et al.  Clinical expertise in the era of evidence-based medicine and patient choice , 2002, ACP journal club.

[26]  Gordon H. Guyatt,et al.  Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice; Users' Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice , 2003, BMJ : British Medical Journal.

[27]  M. Prins,et al.  Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. , 2002, The Cochrane database of systematic reviews.

[28]  A. Lee.  Treatment of venous thromboembolism in cancer patients. , 2005, Thrombosis research.

[29]  A. Martínez,et al.  Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. , 2001, Journal of vascular surgery.

[30]  J. Olsen,et al.  Prognosis of cancers associated with venous thromboembolism. , 2000, The New England journal of medicine.

[31]  J. Ribera,et al.  Low Molecular Weight Heparin (Enoxaparin) Versus Oral Anticoagulant Therapy (Acenocoumarol) in the Long-Term Treatment of Deep Venous Thrombosis in the Elderly: a Randomized Trial , 2000, Thrombosis and Haemostasis.

[32]  M Gent,et al.  Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  W M O'Fallon,et al.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. , 2000, Archives of internal medicine.

[34]  A A Rimm,et al.  Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. , 1999, Medicine.

[35]  S. Carrera,et al.  Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. , 1999, Journal of vascular surgery.

[36]  S. Lopaciuk,et al.  Low Molecular Weight Heparin versus Acenocoumarol in the Secondary Prophylaxis of Deep Vein Thrombosis , 1999, Thrombosis and Haemostasis.

[37]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[38]  A. Gallus.  Prevention of Post-operative Deep Leg Vein Thrombosis in Patients with Cancer , 1997, Thrombosis and Haemostasis.

[39]  M. Gent,et al.  Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis , 1995, Thrombosis and Haemostasis.

[40]  M. Pini,et al.  Low Molecular Weight Heparin versus Warfarin in the Prevention of Recurrences after Deep Vein Thrombosis , 1994, Thrombosis and Haemostasis.

[41]  A. Nicolaides,et al.  Deep vein thrombosis of the leg , 1970 .

[42]  A. Nicolaides,et al.  Deep vein thrombosis of the leg. Is there a "high risk" group? , 1970, American journal of surgery.